Summary & Overview
CPT 0732T: Intramuscular Immunotherapy with Electrical Uptake Enhancement
CPT code 0732T represents a combined therapeutic procedure in which an immunotherapy agent is injected into muscle and electrical pulses are applied to enhance cellular uptake. As an emerging interventional immunotherapy technique, this code captures the integrated act of drug delivery plus adjunctive electostimulation and is relevant where novel biologic delivery methods are increasingly adopted. Nationally, this code is significant for payers evaluating coverage policies for advanced drug-delivery platforms and for providers documenting technology-enabled immunotherapy treatments.
Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise description of the clinical service and typical sites of service, plus an overview of payer considerations, common modifier usage, and related administrative context. The publication outlines benchmarks and policy-relevant points such as coding specificity for combined procedures, implications for claims adjudication, and areas where documentation typically supports medical necessity.
The report provides practical context for billing and coding staff, clinical operations leaders, and policy analysts seeking to understand how CPT code 0732T fits into current coverage environments and administrative workflows. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0732T describes a procedure in which the provider administers an immunotherapy agent intramuscularly and delivers electrical pulses to the treatment site to enhance cellular uptake of the agent. This combined approach pairs a medication injection with adjunctive electrical stimulation to improve therapeutic delivery.
-
Service type: Minimally invasive immunotherapy administration with adjunctive electroporation/electrostimulation
-
Typical site of service: Ambulatory procedure setting or outpatient clinic where intramuscular injections and electrical stimulation devices are available
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a localized or systemic malignancy enrolled in an investigational or advanced immunotherapy protocol who requires enhanced intramuscular delivery of a biologic agent. The patient arrives to an outpatient procedural clinic or hospital outpatient department for a scheduled treatment visit. After standard pre-procedure verification and consent, the provider administers the immunotherapy agent into a selected muscle (commonly the deltoid or vastus lateralis) using aseptic technique. Immediately after injection, the clinical team connects a specialized electroporation device to the muscle region and delivers a series of controlled electrical pulses to transiently increase cell membrane permeability and improve uptake of the immunotherapy. Vital signs and device parameters are monitored during the pulse sequence; local analgesia or conscious sedation may be used per protocol. Post-procedure observation is brief for hemostasis and monitoring for acute adverse effects (pain, local inflammation, arrhythmia if near chest wall), then the patient is discharged with return precautions and follow-up per the therapeutic protocol. Typical sites of service are outpatient clinic, hospital outpatient department, ambulatory surgery center, or research facility conducting clinical trials.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required is substantially greater than typically required for the procedure due to complexity, extended time, or complication. |
52 | Reduced services | Use when the service is partially reduced or eliminated at the physician's discretion. |
53 | Discontinued procedure | Use when the procedure is started but discontinued due to extenuating circumstances or patient condition. |
78 | Return to operating/procedure room for related procedure during the postoperative period | Use when the patient requires an unplanned return to the procedure area for a related procedure during the global period. |
59 | Distinct procedural service | Use when a separate, distinct procedure is performed that is not usually reported together. |
76 | Repeat procedure by same physician | Use when the same procedure is repeated subsequent to the original within the global period. |
77 | Repeat procedure by another physician | Use when another physician repeats the procedure. |
LT | Left side | Use when the procedure is performed on the left side, if laterality reporting is required. |
RT | Right side | Use when the procedure is performed on the right side, if laterality reporting is required. |
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a significant E/M is provided on the same day as the procedure. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 2084P0800X | Medical Oncology | Oncology providers frequently participate in immunotherapy administration and protocols. |
| 207RH0000X | Hematology-Oncology | Specialists managing systemic immunotherapy for hematologic malignancies. |
| 163W00000X | Interventional Pain Management | Providers with expertise in procedure-based delivery and device usage may perform electroporation-assisted injections. |
| 207L00000X | Infectious Disease | Specialists when immunotherapeutic agents are used in infectious disease research or advanced therapy contexts. |
| 208M00000X | Radiation Oncology | Multidisciplinary oncology teams involved in combined-modality protocols that include immunotherapy delivery. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C80.1 | Malignant (primary) neoplasm, unspecified | Used for advanced or metastatic cancers when a specific primary site is not documented but systemic immunotherapy is indicated. |
C79.9 | Secondary malignant neoplasm of unspecified site | Indicates metastatic disease where investigational immunotherapy with enhanced delivery may be considered. |
D61.9 | Aplastic anemia, unspecified | Reflects hematologic conditions where cellular-targeted immunotherapies or cell uptake enhancement techniques may be used in research contexts. |
Z00.6 | Encounter for examination for normal comparison and control in clinical research program | Used for protocol-specified treatment visits within clinical trials. |
R53.83 | Other fatigue | Symptom code that may be used for supportive care visits associated with systemic immunotherapy administration. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
93000 | Electrocardiogram, routine EKG with at least 12 leads; with interpretation and report | May be performed pre-procedure for patients with cardiac risk when electroporation is applied near the chest or in patients with implants. |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | Used for standard intramuscular injections of therapeutic agents when electroporation is not performed or for additional medications during the visit. |
99070 | Supplies and materials (except spectacles), used for patient care, not usually included with the service | Used to report specialized disposables associated with the electroporation device or investigational supplies. |
99213 | Office or other outpatient established patient visit, typically 15 minutes | Commonly used for pre-procedure evaluation and follow-up visits related to immunotherapy administration. |
01999 | Unlisted anesthesia procedure | Applied if non-standard anesthesia or sedation is provided for device tolerability and not covered by specific anesthesia codes. |